Idéal Investisseur
Français English
CAC 40 :
8 157,82 pts
-0.84%


Last updated : 24/04/2026 - 17h35

Stock CELLECTIS (FR0010425595)

Sector : Pharmaceuticals & Biotechnology – Indices : EN GROWTH ALLSHARE, NEXT BIOTECH

Price 3,31 €
Daily change -1,02 %
1 week -11,32 %
1 month 0,00 %
1 year +146,00 %

Last update : 24/04/2026 at 17:35:24 – Source: Euronext

Assurance vie

Market summary

As of 24/04/2026, stock CELLECTIS trades at 3,31 € , with a change of -1,02 % , and a market cap of 238 M€.

Open0,00 €
Previous close3,34 €
Volume175 191
Market cap238 M€
P/EN/A
Dividend / shareN/A
Float turnover0,00 %
MarketEuronext PARIS
Eligible PEA

Price and moving averages

Technical analysis CELLECTIS

50-day moving average3,36 €-1.61 % (below) Pivot3,3 €
Support level2,93 €-11.37 % Resistance level3,63 €+9.80 %
1-month volatility24,96 % Annualised volatility86,47 %
RSI (14d)35 Neutral Stochastic signal (14d)Achat_fort
ATR (14d)0,22 Low volatility CMF (21d)-0,21 Moderate selling pressure
Bollinger bands (20d) Neutral OBV (21d) Neutral (OBV stable)

Analyst consensus and recommendations

Insufficient data.

No analyst recommendation available.

Stock history and statistics

IPO dateFeb 06, 2007
52-week high4,35 €52-week low2,72 €
All-time high41,95 €All-time low0,89 €
1-year volatility86,47 %Beta-0,62

Financial calendar — CELLECTIS

📅
March 19, 2026 Annual results

Recent news — CELLECTIS

The biotech company's stock is among the few showing significant gains this Monday, while the CAC 40 drops by 0.87% during the session. Cellectis has …

Allogene Therapeutics has announced the results of an interim futility analysis of the ALPHA3 pivotal trial evaluating cema-cel, a candidate product d…

Cellectis' flagship program records an intermediate clinical success. The futility analysis of the pivotal ALPHA3 trial, conducted by its partner Allo…

Cellectis is seeing a rebound this Friday, April 10, with its shares trading at €3.158 mid-morning, up more than 4% from the previous day. This recove…

Cellectis, a clinical-stage biotechnology company, presents its 2025 results and an update on its development activities. The company announces the pr…

The biotechnology group Cellectis recorded a 62% increase in its revenue in 2025, driven by its agreements with AstraZeneca and Servier. However, its …

Analyses on CELLECTIS stock

No analysis has been published on this stock yet.

Frequently asked questions about CELLECTIS stock

What does the recent price action of CELLECTIS stock show?

CELLECTIS stock is currently trading around 3,31 €, down 1,02% and down 0,11% over one week.

Is CELLECTIS stock in a support or resistance zone?

Technical levels help place the stock. Support: 2,93 €. Resistance: 3,63 €.

How should the current volatility of CELLECTIS stock be interpreted?

Volatility is around 86,47%.

Ad
Chaque matin
Les signaux techniques du marché,
avant l'ouverture.
CAC 40 · SBF 120 · Signaux · Analystes
🤖
Édition du jour — avant bourse
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Signaux haussiers
+5,2%
+1,8%
+0,9%
📉 Signaux baissiers
-14%
-5,7%
🔄 Avis analystes
▲ 35 €
▼ 80 €
Inscrivez-vous pour tout voir →
Avant 9h chaque matin
Données Euronext
Analyse automatique IA
BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit